Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650206 · ClinicalTrials.gov registry record · Phase 1
Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT02650206: Completed Phase 1 study, sponsored by Stanford University.
NCT02650206 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02650206, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The objective of this study is to test the hypothesis that liraglutide (commonly known as Victoza) can promote an anti-inflammatory macrophage phenotype in human adipose tissue and blood, thereby reducing localized and systemic inflammation which are risk factors for cardiovascular disease and may contribute to hyperglycemia. This will be done after 4 weeks of treatment during which weight will remain stable, and again after 12 weeks, during which liraglutide-related weight loss occurs.
Interventions
- DRUG Victoza (liraglutide) with dietician monitoring
- OTHER Placebo with dietician monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02650206
The ClinicalTrials.gov registry entry for NCT02650206 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Victoza (liraglutide) with dietician monitoring is the first listed.
NCT02650206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02650206 about?
NCT02650206 is a clinical study titled "Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood". The objective of this study is to test the hypothesis that liraglutide (commonly known as Victoza) can promote an anti-inflammatory macrophage phenotype in human adipose tissue and blood, thereby reducing localized and systemic inflammation which are risk factors for cardiovascular disease and may c...
What is the current status of trial NCT02650206?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2015-01. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT02650206?
The interventions under investigation include: Victoza (liraglutide) with dietician monitoring (DRUG), Placebo with dietician monitoring (OTHER).
Who is sponsoring clinical trial NCT02650206?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.